Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Zacks Investment Research8/27/2026Positive
ATRC
AtriCure IncNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$2.62B
P/E Ratio
245.33
EPS
$0.21
Beta
1.26
52W High
$53.50
52W Low
$25.36
50-Day MA
$40.07
200-Day MA
$34.52
Dividend Yield
—
Profit Margin
1.85%
Forward P/E
204.08
PEG Ratio
10.00
About AtriCure Inc
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
Fundamentals
| Revenue (TTM) | $569.62M |
| Gross Profit (TTM) | $434.61M |
| EBITDA | $33.75M |
| Operating Margin | 6.29% |
| Return on Equity | 2.15% |
| Return on Assets | 1.25% |
| Revenue/Share (TTM) | $11.81 |
| Book Value | $10.15 |
| Price-to-Book | 5.17 |
| Price-to-Sales (TTM) | 4.60 |
| EV/Revenue | 4.515 |
| EV/EBITDA | 66.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.80% |
| Shares Outstanding | $50.87M |
| Float | $48.81M |
| % Insiders | 3.79% |
| % Institutions | 105.72% |
Historical Volatility
HV 10-Day
42.64%
HV 20-Day
34.57%
HV 30-Day
44.01%
HV 60-Day
47.26%
HV Rank
34.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($51.67 target)
3
Strong Buy5
Buy2
HoldLatest News
AtriCure: Promising Cardiovascular Surgical Platform
AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
Seeking Alpha8/21/2026Neutral
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
MarketBeat8/12/2026Neutral
AtriCure to Participate at Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCure's management is scheduled to participate in meetings at the 11th Annual Needham Virtual MedTech & Diagnostics Conference on Monday, August 10, 2026. AtriCure will also.
Business Wire7/27/2026Neutral
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
Seeking Alpha7/24/2026Neutral
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research7/24/2026Positive
AtriCure Reports Second Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu.
Business Wire7/23/2026Neutral
AtriCure to Announce Second Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listeni.
Business Wire7/2/2026Neutral
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research6/19/2026Positive
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Zacks Investment Research6/11/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ATRC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026